Loading stock data…
Charles River Laboratories International (CRL)
$225.57+9.82 (+4.55%)
Market ClosedLast close Jun 29
Charles River Laboratories International, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Charles River Laboratories International, Inc. in the Healthcare sector is trading at $225.57 with a market capitalization of $9.0B. Wall Street consensus targets $215.33 (15 analysts), implying a -4.5% move over the next 12 months. The stock is currently near its 52-week high of $228.88, remaining 25.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $995.83M↑ | $994.23M↓ | $1.00B↓ | $1.03B↑ | $984.17M |
| Gross Profit | $294.66M↓ | $309.68M↓ | $338.79M↓ | $357.07M↑ | $317.73M |
| Operating Income | $119.90M↑ | $92.53M↓ | $133.80M↑ | $100.13M↑ | $74.67M |
| Net Income | -$14.84M↑ | -$276.56M↓ | $54.42M↑ | $52.33M↑ | $25.47M |
Peer Comparison
JNJUNHPFE
Fundamentals
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.01B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.28%
Volume
Today's trading volume
905,581
Recent News
Is Charles River Laboratories International, Inc. (CRL) A Good Stock To Buy Now?
Is CRL a good stock to buy? We came across a bullish thesis on Charles River Laboratories International, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on CRL. Charles River Laboratories International, Inc.’s share was trading at $202.10 as of June 24th. CRL’s trailing and forward P/E were 25.07 and 18.15 respectively […]
Is Charles River (CRL) Quietly Redefining Its Moat Through Lilly’s AI-Driven TuneLab Collaboration?
In June 2026, Eli Lilly’s Lilly TuneLab announced a collaboration under which Charles River Laboratories will provide standardized nonclinical testing services to AI/ML-enabled biotech companies using the TuneLab drug discovery platform. This collaboration ties Charles River more closely into Lilly’s Catalyze360 ecosystem, potentially deepening its role in data-rich, AI-enhanced preclinical research workflows. We’ll now examine how Charles River’s deeper integration into Lilly’s AI-driven...
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?
Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.
How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks?
Despite underperforming its industry peers over the past year, analysts remain highly bullish on Charles River Laboratories' long-term prospects.
Charles River collaborates with Lilly TuneLab platform
By incorporating nonclinical testing services, the partnership seeks to standardise testing protocols across organisations.